KEYTRUDA Sales & FDA Approvals Trajectory



Initial FDA Approvals	**Melanoma** (2L+)	**Melanoma** (1L), **NSCLC** ≥1% PD-L1 (2L+)	**NSCLC** ≥50% PD-L1 (1L), **SCCHN** post-platinum (2L+)	**cHL** adult & ped (3L+), **Urothelial** post-platinum (1L[a] & 2L), **MSI-High** (2L+), **Gastric** PD-L1+ (3L+), **NSCLC** non-sq chemo combo (1L)	**NSCLC** Non-Sq chemo combo no ALK / EGFR mut (1L), **NSCLC** Sq chemo combo (1L), **MCC** (2L+), **HCC** post-sorafenib (2L+), **PMBCL** (2L+), **Cervical** post-chemo PD-L1+ (2L+)	**Melanoma** (Adj.), **RCC** axitinib combo (1L), **SCCHN** chemo combo (1L) or mono PD-L1+ (1L), **SCLC** (3L+), **ESCC** CPS≥10 (2L+), **Endometrial** Lenvatinib combo not MSI-H (2L+)	**NMIBC** BCG unresponsive high-risk with CIS (2L+), **MSI-High CRC** unresectable (1L), **TNBC** CPS≥10 (1L), **cSCC** (2L+), **TMB-H** adult & ped (2L+), **cHL** adult & ped (2L+), **Multiple** 400mg dose at all approved adult indications	**RCC** lenvatinib combo (1L), **RCC** high-risk clear cell (Adj.), **Cervical** chemo combo +/- bev PD-L1+ (1L), **TNBC** (Neo Adj.), **Endometrial** Lenvatinib combo (2L+), **GEJ** chemo combo (1L), **GEJ** HER2+ combo (1L), **cSCC** (2L+)	**Endometrial** MSI-H (2L+)	**Urothelial** cisplatin ineligible Padcev combo (1L), **NSCLC** post resection & chemo (Adj.)			

(a) Cisplatin ineligible (b) Recruiting or active studies associated with pembrolizumab listed on clinicaltrials.gov (up to 9/11/2023)

Note: 2023+ sales estimates based on sell-side consensus

Andrew Pannu @andrewpannu

Summary of Pivotal Keytruda Trials

Indication	Setting	Key Trial(s)	Year of FDA Approval
Melanoma	2L+	KEYNOTE-002	2014
	1L	KEYNOTE-006	2015
	Adjuvant	KEYNOTE-054	2019
SCCHN	Post-platinum	KEYNOTE-012, KEYNOTE-040	2016
	1L Mono PD-L1+ / 1L combo w/ chemo	KEYNOTE-048	2019
cHL	3L+	KEYNOTE-087, KEYNOTE-204	2017
	2L+ pediatric	KEYNOTE-204	2020
Urothelial	2L+	KEYNOTE-045	2017
	1L post-platinum	KEYNOTE-052	2017
	2L+ NMIBC high-risk	KEYNOTE-057	2020
	1L w/ Padcev	KEYNOTE-869	2023
MSI-High CRC	1L	KEYNOTE-177	2020
MSI-High	2L+	Multiple (5)	2017
	2L+	KEYNOTE-164, KEYNOTE-158, KEYNOTE-051	2023
GEJ	3L+	KEYNOTE-059	2017
	1L	KEYNOTE-590	2021
	1L HER2+	KEYNOTE-811	2021
Cervical	2L+ post-chemo PD-L1+	KEYNOTE-158	2018
	1L w/ bev PD-L1+	KEYNOTE-826	2021
Endometrial	2L+ w/ lenvatinib, not MSI-H	KEYNOTE-146	2019
	2L+ w/ lenvatinib	KEYNOTE-755	2021
	2L+ MSI-High	KEYNOTE-158	2022

Indication	Setting	Key Trial(s)	Year of FDA Approval
NSCLC	2L+ ≥1% PD-L1	KEYNOTE-010	2015
	1L+ ≥50% PD-L1	KEYNOTE-024	2016
	1L chemo combo non-sq	KEYNOTE-021	2017
	1L chemo combo non-sq no EGFR / ALK mut.	KEYNOTE-189	2018
	1L chemo combo sq	KEYNOTE-407	2018
	1L mono	KEYNOTE-042	2019
	Adjuvant	KEYNOTE-091	2023
HCC	Post-sorafenib	KEYNOTE-244	2018
MCC	2L+	KEYNOTE-017	2018
RCC	1L w/ axitinib	KEYNOTE-426	2019
	1L w/ lenvatinib	KEYNOTE-581	2021
	Adjuvant high-risk	KEYNOTE-564	2021
SCLC	3L+	KEYNOTE-158, KEYNOTE-028	2019
ESCC	2L+ CPS ≥10	KEYNOTE-181, KEYNOTE-180	2019
	1L	KEYNOTE-590	2021
TNBC	1L CPS ≥10	KEYNOTE-355	2020
	Neoadjuvant / Adjuvant	KEYNOTE-522	2021
TMB-High	TMB-H ≥10	KEYNOTE-158	2020
cSCC	2L+	KEYNOTE-629	2020 & 2021
PMBCL	2L+	KEYNOTE-170	2018

Andrew Pannu  @andrewpannu